TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05045404

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Cause of deathSlow enrollment, also funding or business Automatic label, confidence 0.5, unverified. How labels are made.
“Study closed due to funding, 0 patient accrual.”

The sponsor’s own words in the registry.

Life of this trial

2021202220232024Planned start2021-06-16 (planned)Registered2021-09-07Withdrawn (as of)2023-09-13

Vital statistics

Status
Withdrawn
Phase
Phase 2
Sponsor
M.D. Anderson Cancer Center
Sponsor type
University, hospital or other
Conditions
Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions
Poziotinib Hydrochloride; 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
Participants
0

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.